Large-scale generation of human red blood cells for transfusion therapy

大规模产生用于输血治疗的人类红细胞

• 批准号: 7994247
• 负责人: YOSEF REFAELI
• 金额: $ 15.14万
• 依托单位: TAIGA BIOTECHNOLOGIES, INC.
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-09-01 至 2012-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7994247
• 关键词: Acute; Adult; Anemia; Animals; Binding; Biological Preservation; Blood; Bone Marrow; Cell Line; Cell Size; Cell physiology; Cell surface; Cells; Chimeric Proteins; Clinical; Clinical Trials; Data; Dependency; Drops; Erythrocyte Transfusion; Erythrocytes; Failure; Generations; Genetic; Genome; Goals; Hematological Disease; Hematopoietic; Hematopoietic stem cells; Hemoglobin; Human; Human Cell Line; Immunocompromised Host; In Vitro; Kinetics; Life; Lymphoid Cell; Medical; Methods; Modification; Mus; Nature; Nuclear; Operative Surgical Procedures; Oxygen; Patients; Phase; Procedures; Proteins; Protocols documentation; Public Health; Serum; Source; Stem cells; System; TFRC gene; Technology; Tensile Strength; Testing; Time; Transduction Gene; Transfusion; Trauma; Umbilical Cord Blood; Viral; aging population; base; cell type; clinical application; cytokine; embryonic stem cell; fetal; global health; human adult stem cell; irradiation; large scale production; model development; new technology; novel; novel strategies; peripheral blood; progenitor; public health relevance; reconstitution; stemness

DESCRIPTION (provided by applicant): Using a method of retroviral gene transduction we have been able to generate conditionally immortalized long-term hematopoietic stem cell lines from primary human cord blood stem cells. Phase I of this project includes applying newly discovered non- viral technology to generate human cell lines and the subsequent differentiation of those cells into human red blood cells. In addition, the project includes testing the function of these cells in small animals. Phase II of the project will entail optimizing large-scale production of protein transduced long-term hematopoietic stem cells and large-scale production of red blood cells for eventual testing in larger animals and human clinical trials. PUBLIC HEALTH RELEVANCE: This project seeks to optimize a novel method to generate large amounts of human red blood cells for clinical use from human adult stem cells. Once this method has been validated for large-scale production, the long-term goal for benefiting public health will be to use this system to generate red blood cells for clinical applications across a variety of global health conditions including, but not limited to, blood disorders, surgeries and in cases of acute trauma.

描述（由申请人提供）：使用逆转录病毒基因转导的方法，我们已经能够从原代人脐带血干细胞中产生有条件永生的长期造血干细胞系。该项目的第一阶段包括应用新发现的非病毒技术来产生人类细胞系，并随后将这些细胞分化为人类红细胞。此外，该项目还包括在小动物身上测试这些细胞的功能。该项目的第二阶段将需要优化大规模生产蛋白质转导的长期造血干细胞和大规模生产红细胞，以便最终在大型动物和人体临床试验中进行测试。